找回密码
 立即注册

微信扫码登录

搜索

[晚期无驱动一线] KEYNOTE-598:帕博利珠加伊匹单抗或安慰剂治疗PD-L1≥50%的转移性非小细胞肺癌

[复制链接]
英俊潇洒 发表于 2021-2-21 14:42:08 | 显示全部楼层 |阅读模式
Pembrolizumab Plus Ipilimumab or Placebo for Metastatic Non–Small-Cell Lung Cancer With PD- L1 Tumor Proportion Score ‡ 50%: Randomized, Double-Blind Phase III KEYNOTE-598 Study (JCO, IF:32.956)
  • Boyer Michael,Şendur Mehmet A N,Rodríguez-Abreu Delvys et al. Pembrolizumab Plus Ipilimumab or Placebo for Metastatic Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%: Randomized, Double-Blind Phase III KEYNOTE-598 Study.[J] .J Clin Oncol, 2021, undefined: JCO2003579.
PURPOSE 目的Pembrolizumab monotherapy is standard first-line therapy for metastatic non-small-cell lung cancer (NSCLC) withprogrammed death ligand 1 (PD-L1) tumor proportion score (TPS) ≥ 50% without actionable driver mutations. It is not known whether adding ipilimumab to pembrolizumab improves efficacy over pembrolizumab alone in this population.
帕博利珠单抗是治疗程序性死亡配体1(PD-L1)肿瘤比例评分≥50%且无有效驱动基因突变的转移性非小细胞肺癌的标准一线治疗方案。目前尚不清楚在这一人群中添加伊匹单抗是否比单独使用帕博利珠更有效。


METHODS 方法In the randomized, double-blind, phase III KEYNOTE-598 trial (ClinicalTrials.gov identifier: NCT03302234), eligible patients with previously untreated metastatic NSCLC with PD-L1 TPS ≥ 50% and no sensitizing or aberrations were randomly allocated 1:1 to ipilimumab 1 mg/kg or placebo every 6 weeks for up to 18 doses; all participants received pembrolizumab 200 mg every 3 weeks for up to 35 doses. Primary end points were overall survival and progression-free survival.
在随机、双盲、III期Keynote-598试验(ClinicalTrials.gov标识符:NCT03302234)中,符合条件的PD-L1 TPS≥为50%且无敏感或突变的转移性非小细胞肺癌患者被随机分配为1:1,每6周1 mg/kg或安慰剂,最多18次;所有参与者每3周服用帕博利珠单抗200 mg,最多35次。主要终点是总存活率和无进展存活率。


RESULTS 结果Of the 568 participants, 284 were randomly allocated to each group. Median overall survival was 21.4 months for pembrolizumab-ipilimumab versus 21.9 months for pembrolizumab-placebo (hazard ratio, 1.08; 95% CI, 0.85 to 1.37; = .74). Median progression-free survival was 8.2 months for pembrolizumab-ipilimumab versus 8.4 months for pembrolizumab-placebo (hazard ratio, 1.06; 95% CI, 0.86 to 1.30; = .72). Grade 3-5 adverse events occurred in 62.4% of pembrolizumab-ipilimumab recipients versus 50.2% of pembrolizumab-placebo recipients and led to death in 13.1% versus 7.5%. The external data and safety monitoring committee recommended that the study be stopped for futility and that participants discontinue ipilimumab and placebo.
在568名参与者中,284名被随机分配到每组。帕博利珠-伊匹单抗的中位总生存期为21.4个月,而帕博利珠-安慰剂为21.9个月(风险比为1.08;95%CI为0.85至1.37;=0.74)。帕博利珠-伊匹单抗的中位无进展生存期为8.2个月,而帕博利珠-安慰剂的中位无进展生存期为8.4个月(风险比为1.06;95%CI为0.86至1.30;=0.72)。接受帕博利珠单抗-伊匹单抗的患者中发生3-5级不良事件的比例为62.4%,而接受帕博利珠单抗-安慰剂的患者中发生3-5级不良事件的比例为50.2%,导致死亡的比例分别为13.1%和7.5%。外部数据和安全监测委员会建议停止这项研究,因为这是徒劳的,参与者应该停止使用伊匹单抗和安慰剂。


CONCLUSION 结论Adding ipilimumab to pembrolizumab does not improve efficacy and is associated with greater toxicity than pembrolizumab monotherapy as first-line treatment for metastatic NSCLC with PD-L1 TPS ≥ 50% and no targetable or aberrations. These data do not support use of pembrolizumab-ipilimumab in place of pembrolizumab monotherapy in this population.
增加伊匹单抗,与帕博利珠联合治疗PD-L1 TPS≥为50%且无靶向性或畸变的转移性非小细胞肺癌作为一线治疗,并不能提高疗效,且毒性大于帕博利珠单抗。这些数据不支持在该人群中使用帕博利珠-伊匹单抗来代替帕博利珠单一疗法。

本帖共 1 条回复,登录后VIP可查看

给我们建议|手机版|阳光肺科 ( 粤ICP备2020077405号-1 )

GMT+8, 2026-11-23 00:14

Powered by Discuz! X3.5

© 2001-2026 Discuz! Team.

快速回复 返回顶部 返回列表